Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

A Study to Test if TEV-50717 is Effective in Relieving Tics Associated With Tourette Syndrome (TS)

ClinicalTrials.gov ID: NCT03571256

Public ClinicalTrials.gov record NCT03571256. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 4, 2026, 2:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Well-Controlled, Fixed-Dose Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tics Associated With Tourette Syndrome

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

Standard placebo-controlled, double-blind study design (TEV-50717 \[low dose and high dose\] vs. placebo in a 1:1:1 ratio) was chosen to determine whether study drug treatment results in a statistically significant effect on the tics in participants with TS.

Study identification

NCT ID
NCT03571256
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Enrollment
158 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
6 Years to 16 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 30, 2018
Primary completion
Dec 8, 2019
Completion
Dec 8, 2019
Last update posted
Nov 8, 2021

2018 – 2019

United States locations

U.S. sites
19
U.S. states
13
U.S. cities
17
Facility City State ZIP Site status
Teva Investigational Site 060-0160 Gainesville Florida 32608
Teva Investigational Site 060-0166 Gulf Breeze Florida 32561-4458
Teva Investigational Site 060-0161 Miami Florida 33136-2107
Teva Investigational Site 060-0151 Orlando Florida 32801
Teva Investigational Site 060-0153 Orlando Florida 32819
Teva Investigational Site 060-0168 Atlanta Georgia 30329
Teva Investigational Site 060-0155 Chicago Illinois 60612
Teva Investigational Site 060-0164 Chicago Illinois 60634
Teva Investigational Site 060-0152 Indianapolis Indiana 46256
Teva Investigational Site 060-0158 Louisville Kentucky 40202
Teva Investigational Site 060-0167 Rockville Maryland 20852-4219
Teva Investigational Site 060-0165 Ann Arbor Michigan 48105
Teva Investigational Site 060-0170 Bridgeton Missouri 63044
Teva Investigational Site 060-0154 New York New York 10036
Teva Investigational Site 060-0169 Charleston South Carolina 29414-5834
Teva Investigational Site 060-0157 Memphis Tennessee 38157
Teva Investigational Site 060-0156 Nashville Tennessee 37232-2551
Teva Investigational Site 060-0163 Fort Worth Texas 76104
Teva Investigational Site 060-0162 Everett Washington 98201-4077

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 37 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03571256, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 8, 2021 · Synced Sep 4, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03571256 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →